Biotech ETFs Stage Solid Comeback at the Start of 2024

zacks01-09

The biotech space staged a strong comeback at the start of 2024, with many stocks and ETFs scaling new one-year highs. The gains are being driven by multibillion-dollar deals, upbeat clinical results ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2402262137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-09 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2402262137","market":"us","top_or_hot":-1,"title":"Biotech ETFs Stage Solid Comeback at the Start of 2024","media":"zacks","content":"<div>\n<p>The biotech space staged a strong comeback at the start of 2024, with many stocks and ETFs scaling new one-year highs. The gains are being driven by multibillion-dollar deals, upbeat clinical results ...</p>\n\n<a href=\"https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024\">Source Link</a>\n\n</div>\n","source":"zacks_fund_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech ETFs Stage Solid Comeback at the Start of 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech ETFs Stage Solid Comeback at the Start of 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-09 12:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024><strong>zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech space staged a strong comeback at the start of 2024, with many stocks and ETFs scaling new one-year highs. The gains are being driven by multibillion-dollar deals, upbeat clinical results ...</p>\n\n<a href=\"https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024","article_id":"2402262137","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2402262137","pubTimestamp":1704772800,"sourceInfo":{"source_id":"zacks_fund_highlight","name":"Zacks"},"weMediaInfo":null,"summary":"The biotech space staged a strong comeback at the start of 2024, with many stocks and ETFs scaling new one-year highs. The gains are being driven by multibillion-dollar deals, upbeat clinical results ","collect":0,"end_time":0,"defaultTopTitle":"zacks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4139":"生物科技","RYZB":"RayzeBio, Inc.","BK4566":"资本集团","03165":"华夏欧优股对冲","BK4007":"制药","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SSI":"Stage Stores Inc","NVO":"诺和诺德","BK4578":"CAR-T","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","GRCL":"亘喜生物","VRTX":"福泰制药","BK4568":"美国抗疫概念","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LLY":"礼来","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","NVS":"诺华","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","HARP":"Harpoon Therapeutics Inc.","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4581":"高盛持仓","OMGA":"Omega Therapeutics","ABBV":"艾伯维公司","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","FDN":"First Trust Dow Jones Internet I","AZN":"阿斯利康","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","MRNA":"Moderna, Inc.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","CRSP":"CRISPR Therapeutics AG","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","RHHBY":"罗氏控股","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","AMAM":"Ambrx Biopharma Inc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","KRTX":"Karuna Therapeutics","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4567":"ESG概念"},"translate_title":"生物科技ETF将于2024年初强势回归","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"VRTX":1,"SSI":1,"RYZB":1,"RHHBY":1,"OMGA":1,"NVS":1,"NVO":1,"MRNA":1,"LLY":1,"KRTX":1,"HARP":1,"GRCL":1,"CRSP":1,"AMAM":1,"AZN":1,"FDN":0.9,"03165":0.6},"content_text":"The biotech space staged a strong comeback at the start of 2024, with many stocks and ETFs scaling new one-year highs. The gains are being driven by multibillion-dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.In particular, SPDR S&P Biotech ETF (XBI Quick QuoteXBI  -  Free Report)    , Vaneck Biotech ETF (BBH Quick QuoteBBH  -  Free Report)    , iShares Biotechnology ETF (IBB Quick QuoteIBB  -  Free Report)    , iShares Biotechnology ETF (IBBQ Quick QuoteIBBQ  -  Free Report)     and Virtus Lifesci Biotech Products ETF (BBP Quick QuoteBBP  -  Free Report)     have hit new 52-week highs (read: 5 Top-Ranked ETF Winners of December With More Room for Gains).Series of DealsLast month, there were four major acquisitions — Bristol Myers Squibb's (BMY Quick QuoteBMY  -  Free Report)     purchase of Karuna Therapeutics (KRTX) for $14 billion and Roche's (RHHBY) acquisition of Carmot Therapeutics for $3.1 billion, a significant move in the highly competitive obesity market. Bristol Myers also proposed the $4.1 billion acquisition of RayzeBio (RYZB), while AstraZeneca (AZN) concluded a deal to acquire Gracell Biotechnologies (GRCL) for an estimated $1.2 billion. AbbVie (ABBV) executed two large-scale transactions totaling approximately $18.8 billion within a brief period of seven days.This trend of aggressive acquisitions continued into early January. Johnson & Johnson (JNJ Quick QuoteJNJ  -  Free Report)     announced its $2 billion acquisition of Ambrx (AMAM), focusing on cancer treatment, particularly targeted chemotherapy through antibody-drug conjugates. Merck (MRK Quick QuoteMRK  -  Free Report)     followed suit with an $860 million deal for Harpoon Therapeutics (HARP). Meanwhile, Novartis (NVS) clinched a deal with privately held Calypso Biotech, a firm exploring treatments for autoimmune diseases.Regulatory Approvals WinA flurry of regulatory approvals has been driving biotech stocks higher. Crispr Therapeutics (CRSP) achieved a milestone by gaining FDA approval for its groundbreaking CRISPR-based gene-editing drug. Vertex Pharmaceuticals (VRTX) made significant progress with its non-opioid pain treatment and Moderna (MRNA) soared due to promising results for its Merck-partnered cancer vaccine in melanoma patients (read: Healthcare ETFs Start 2024 on a Positive Note).Emerging Opportunities in Weight-Loss Drug TreatmentsThe landscape of obesity treatment is experiencing a significant transformation, characterized by promising developments and lucrative potential.The new year has been marked by noteworthy advancements from Eli Lilly (LLY) and Novo Nordisk (NVO) in the realm of obesity management. Eli Lilly initiated a direct-to-consumer platform, facilitating connections between patients and independent healthcare providers, while ensuring support and streamlined drug delivery via third-party pharmacies. Novo Nordisk collaborated with Omega Therapeutics (OMGA) to explore novel obesity treatments and partnered with Cellarity, a private firm, to address a specific type of steatohepatitis linked to obesity.ETFs in FocusSPDR S&P Biotech ETF (XBI Quick QuoteXBI  -  Free Report)    SPDR S&P Biotech ETF offers exposure to the biotech corner of the healthcare sector by tracking the S&P Biotechnology Select Industry Index. It holds 124 stocks in its basket with modest exposure across various securities. SPDR S&P Biotech ETF has amassed $6.8 billion in its asset base and charges 35 bps in annual fees. It trades in an average daily volume of 11.3 million shares and has a Zacks ETF Rank #3 (Hold).VanEck Vectors Biotech ETF (BBH Quick QuoteBBH  -  Free Report)    VanEck Vectors Biotech ETF offers exposure to 24 companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment by tracking the MVIS US Listed Biotech 25 Index. VanEck Vectors Biotech ETF has amassed $480 million in its asset base and charges 35 bps in fees per year. It has a Zacks ETF Rank #3 with a High risk outlook (read: Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?).iShares Biotechnology ETF (IBB Quick QuoteIBB  -  Free Report)    iShares Biotechnology ETF provides exposure to 227 U.S. biotechnology and pharmaceutical companies by tracking the NYSE Biotechnology Index. IBB is the most popular fund in the biotech space, with an AUM of $7.6 billion and an expense ratio of 0.45%. iShares Biotechnology ETF has a Zacks ETF Rank #2 (Buy) with a High risk outlook.Invesco Nasdaq Biotechnology ETF (IBBQ Quick QuoteIBBQ  -  Free Report)    Invesco Nasdaq Biotechnology ETF follows the Nasdaq Biotechnology Index and holds 226 stocks in its basket. It has been able to manage assets worth $21.2 million and trades in average daily volume of 16,000 shares. Invesco Nasdaq Biotechnology ETF charges 19 bps in annual fees and has a Zacks ETF Rank #2.Virtus LifeSci Biotech Products ETF (BBP Quick QuoteBBP  -  Free Report)    Virtus LifeSci Biotech Products ETF follows the LifeSci Biotechnology Products Index, which measures the performance of biotechnology companies with at least one drug therapy approved by the FDA. Holding 57 stocks, Virtus LifeSci Biotech Products ETF has accumulated AUM of $17.4 million and charges 79 bps in fees per year. It trades in a volume of 1,000 shares a day on average and has a Zacks ETF Rank #3 with a High risk outlook.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2402262137"}